Novel Antimicrobials and AMR Diagnostics 2019

News

WHO calls for data to establish pre-clinical pipeline overview

The World Health Organization has published a first call to establish a pre-clinical pipeline overview in the field of AMR. GARDP supports the activities.

With this call, WHO - in collaboration with R&D funders and companies - aims to gather data on antibacterial treatments that are in pre-clinical development. To better understand the current pre-clinical antibacterial R&D landscape and share this with the wider scientific, policy and investor communities, WHO is undertaking its first review of the pre-clinical pipeline to tackle resistant bacterial infections.

The aim of the pre-clinical pipeline review is to encourage greater investment into pre-clinical pipeline projects, and ensuring that promising products are pulled through to the market, are affordable and available to the patients who need them. WHO is undertaking the pre-clinical pipeline review with support from GARDP. The call builds on the WHO global analysis of antibacterial treatments that currently are in clinical development (phase 1-3) https://www.who.int/medicines/areas/rational_use/antibacterial_agents_clinical_development/en/

https://www.who.int/medicines/areas/rational_use/prioritization-of-pathogens/en/


To get involved, companies, institutions and individuals are invited to submit data on their pre-clinical pipeline products that target the WHO Priority Pathogens, TB and/or Clostridium difficile. Please submit your data at the following link: https://www.who.int/medicines/access/antimicrobial_resistance/en/

Deadline for submission is 18 March 2019.

WHO will review the data collected, share it with all contributors and make it available online , as well as publishing it in a WHO publication. It will be shared with relevant private and public funders, the Global AMR R&D Hub, governments and other relevant stakeholders. It is time to shed light on the tremendous work ongoing in the pre-clinical stage of R&D and ensuring that products, including alternative approaches, reach the market to effectively combat AMR. In case of questions please revert to Sarah Paulin (paulins@who.int).